Paper
NJC
12 W. Ren, Z. Qiao, H. Wang and L. Zhang, Med. Res. Rev.,
2003, 23, 519–534.
HCT-116 cells. Preliminary biological activity studies showed
that compound 10v could inhibit the colony formation and
migration of HCT-116 cells. Besides, the Hoechst 33258 staining
assay and flow cytometry revealed that treatment of compound
10v induced the apoptosis of HCT-116 cells in a concentration-
dependent manner, whereas it had no effect on the cell cycle
of HCT-116 cells. Also, WB analysis further confirmed that
HCT-116 cells treated with compound 10v exhibited depressed
expression of tubulin, HIF-1a, HK-2, and PFK compared to the
control group, suggesting that tubulin, HIF-1a, HK-2, and PFK
could be the potential pharmacophore targets of compound 10v.
Results from the molecular docking study further suggest that
tubulin is a potential target for compound 10v. Our studies
suggest that compound 10v could be further optimized and
evaluated as a new anti-tumor agent.
´
13 P. Garcıa-Maceira and J. Mateo, Oncogene, 2009, 28,
313–324.
14 M. V. Blagosklonny, Cell Cycle, 2004, 3, 1537–1542.
15 J. Fang, C. Xia, Z. Cao, J. Z. Zheng, E. Reed and B. H. Jiang,
FASEB J., 2005, 19, 342–353.
16 S. Mirzoeva, N. D. Kim, K. Chiu, C. A. Franzen, R. C. Bergan
and J. C. Pelling, Mol. Carcinog., 2008, 47, 686–700.
17 M. Singh, M. Kaur and O. Silakari, Eur. J. Med. Chem., 2014,
84, 206–239.
18 G. R. Beecher, J. Nutr., 2003, 133, 3248–3254.
19 J. L. Gao and Y. G. Chen, BioMed Res. Int., 2015, 2015, 354143.
´
20 L. Conesa-Milian, E. Falomir, J. Murga, M. Carda, E. Meyen,
S. Liekens and J. A. Marco, Eur. J. Med. Chem., 2018, 147,
183–193.
21 M. M. Mita, L. Sargsyan, A. C. Mita and M. Spear, Expert
Opin. Invest. Drugs, 2013, 22, 317–328.
Conflicts of interest
22 M. J. Perez-Perez, E. M. Priego, O. Bueno, M. S. Martins,
M. D. Canela and S. Liekens, J. Med. Chem., 2016, 59,
8685–8711.
No potential conflicts of interest were disclosed.
23 X. Deng, Z. Wang, J. Liu, S. Xiong, R. Xiong, X. Cao, Y. Chen,
X. Zheng and G. Tang, RSC Adv., 2017, 7, 38171–38178.
24 J. Cuzick, F. Otto, J. A. Baron, P. H. Brown, J. Burn,
P. Greenwald, J. Jankowski, C. La Vecchia, F. Meyskens,
H. J. Senn and M. Thun, Lancet Oncol., 2009, 10, 501–507.
25 I. Phillips, R. Langley, D. Gilbert and A. Ring, Clin. Oncol.,
2013, 25, 333–335.
Acknowledgements
This work was financially supported by Hunan Province Coop-
erative Innovation Center for Molecular Target New Drug Study
(0223-0002-0002000-49) and Innovation Platform Open Foun-
dation of Education, Department of Hunan province (contract
grant number 16K079, 17K082).
26 M. Gao, Q. Kong, H. Hua, Y. Yin, J. Wang, T. Luo and
Y. Jiang, Oncotarget, 2016, 7, 16349–16361.
27 S. Saha, S. Mukherjee, P. Khan, K. Kajal, M. Mazumdar,
A. Manna, S. Mukherjee, S. De, D. Jana, D. K. Sarkar and
T. Das, Cancer Res., 2016, 76, 2000–2012.
References
1 A. Anighoro, J. Bajorath and G. Rastelli, J. Med. Chem., 2014,
57, 7874–7887.
28 L. Lu, H. C. Sun, W. Zhang, Z. T. Chai, X. D. Zhu, L. Q. Kong,
W. Q. Wang, K. Z. Zhang, Y. Y. Zhang, Q. B. Zhang, J. Y. Ao,
J. Q. Li, L. Wang, W. Z. Wu and Z. Y. Tang, PLoS One, 2013,
8, e65023.
2 D. Raffa, B. Maggio, M. V. Raimondi, F. Plescia and G. Daidone,
Eur. J. Med. Chem., 2017, 142, 213–228.
3 M. Lopez-Lazaro, Curr. Med. Chem.: Anti-Cancer Agents,
2002, 2, 691–714.
29 B. Pennarun, J. H. Kleibeuker, W. Boersma-van Ek, F. A.
Kruyt, H. Hollema, E. G. de Vries and S. de Jong, J. Pathol.,
2013, 229, 410–421.
4 Z. Wang, X. Deng, R. Xiong, S. Xiong, J. Liu, X. Cao, X. Lei,
Y. Chen, X. Zheng and G. Tang, MedChemComm, 2017, 9,
305–315.
30 S. Kawakami, Y. Kageyama, Y. Fujii, K. Kihara and
H. Oshima, Anticancer Res., 2001, 21, 213–219.
31 P. Patrignani and C. Patrono, J. Am. Coll. Cardiol., 2016, 68,
967–976.
5 R. N. Gacche, R. J. Meshram, H. D. Shegokar, D. S. Gond,
S. S. Kamble, V. N. Dhabadge, B. G. Utage, K. K. Patil and
R. A. More, Arch. Biochem. Biophys., 2015, 577–578, 35–48.
6 L. Marzocchella, M. Fantini, M. Benvenuto, L. Masuelli,
I. Tresoldi, A. Modesti and R. Bei, Recent Pat. Inflammation 32 A. Grada, M. Otero-Vinas, F. Prieto-Castrillo, Z. Obagi and
Allergy Drug Discovery, 2011, 5, 200–220.
V. Falanga, J. Invest. Dermatol., 2017, 137, e11–e16.
7 M. Serafini, I. Peluso and A. Raguzzini, Proc. Nutr. Soc., 33 C. J. Sherr, Science, 1996, 274, 1672–1677.
2010, 69, 273–278.
34 A. Triantafyllou, I. Mylonis, G. Simos, S. Bonanou and
8 K. I. Alzand and M. A. Mohamed, J. Pharm. Res., 2012, 5,
4013–4020.
9 D. Pal and P. Verma, Int. J. Pharm. Pharm. Sci., 2013, 5,
A. Tsakalof, Free Radical Biol. Med., 2008, 44, 657–670.
35 Y. Hu, J. Liu and H. Huang, J. Cell. Biochem., 2013, 114,
498–509.
95–98.
36 Y. Liu, C. K. Veena, J. B. Morgan, K. A. Mohammed,
M. B. Jekabsons, D. G. Nagle and Y. D. Zhou, J. Biol. Chem.,
2009, 284, 5859–5868.
10 O. N. Voskresensky and A. P. Levitsky, Curr. Med. Chem.,
2002, 2, 691–714.
11 Y. Li, H. Fang and W. Xu, Mini-Rev. Med. Chem., 2007, 7, 37 D. Xu, J. Jin, H. Yu, Z. Zhao, D. Ma, C. Zhang and H. Jiang,
663–678.
J. Exp. Clin. Cancer Res., 2017, 36, 44–54.
New J. Chem.
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2019